Register
Register

SCIENTIFIC PROGRAMME

8.00 - 8.25 am

CLINICAL

EARLY CAREER DEVELOPMENT

LABORATORY

NURSING AND PHARMACY

7.00 - 8.00 am

Registration

EDUCATION SESSION 1

Acute Myeloid Leukaemia

Decoding AML: Bridging Genomics and Clinical Practice

Moderator: Dr Ong Tee Chuan

Interpreting the Trephine:

Post-Therapy and Granulomatous Challenges

Moderator: Dr Thatcheiany Kumariah

Nursing and Pharmacy
Education Session 1

Moderator: SN Selvemalini Muruvin

8.00 - 8.25 am

Targeting the Genome: Precision Medicine Approaches in AML

Dr Haris Fadzillah

Benign and Reactive Histological Changes in BMT

Prof Dr Noraidah Masir

Safe Chemotherapy Management: Defining Nursing and Pharmacist Roles from Verification to Delivery

Miss Teh Hui Han

8.25 - 8.50 am

From ‘7+3’ to Smart Drugs: The Therapeutic Revolution in AML

Prof Dr Ng Soo Chin

Bone Marrow Trephine Biopsy Assessment After Chemotherapy

Prof Dr Noraidah Masir

Overview of Haematological Malignancies: A Nursing Perspective

Puan Azizan binti Mohd Isa

8.50 - 9.15 am

Minimal Residual Disease and AML Transplantation: The MRD-Guided Era

Prof Dr Koh Liang Piu

Diagnostic challenges in Large B cell lymphoma

Prof Dr Noraidah Masir

Preventing Deconditioning and Promoting Functional Recovery in Haematology Patients: Practical Strategies for Nurses

Dr Tan Jin Hui

9.15 - 9.30 am

Panel Discussion

Panel Discussion

Panel Discussion

9.30 - 10.00 am

Industry Showcase / Poster walk

10.00 - 10.30 am

Opening Ceremony

10.30 - 11.15 am

Plenary Lecture

EDUCATION SESSION 2

Lymphoma
Modern Management of Hodgkin Lymphoma: Balancing Cure, Toxicity, and Quality of Life

Moderator: Dr Tan Sen Mui

Haemostasis and Thrombosis
From Bleeding to Clotting: Clinical Challenges in Haemostasis and Thrombosis

Moderator: Dr Cheong Chin Sum

Advances in Flow Cytometry
MRD Assessment in B-ALL

Moderator: Dr Nabeelah Binti Abdul Khalid

Nursing and Pharmacy
Education Session 2

Moderator: Miss Priyadharshini
Ramasamy

11.15 - 11.40 am

11.40 - 12.05 pm

12.05 - 12.30 pm

12.30 - 12.45 pm

Epidemiology of Hodgkin Lymphoma: Global Patterns, Local Realities

Prof Dr Gan Gin Gin

Optimizing Frontline Therapy in Hodgkin Lymphoma: Balancing Efficacy and Late Effects

Dr Michelle Poon

Managing Relapsed Hodgkin Lymphoma: Integrating Transplantation and Immunotherapy

TBC

Panel Discussion

How I Treat Bleeding Disorders: From Laboratory Evaluation to Bedside Management

Dr Veena Selvaratnam

How I Treat Venous Thromboembolism: The Nuances of Clinical Management

Dr Andy Tang

How I Treat Thrombocytopenia: From First Platelet Count to Targeted Therapy

Dr Nur Aini Syakirah

Panel Discussion

Current Practice of BCP-ALL MRD in Flow Cytometry and Next Generation Flow

Dr Amitav Mohanty

BCP-ALL MRD: Case Studies Discussion

Dr Amitav Mohanty

Panel Discussion

Weight-Adjusted Chemotherapy Dosing in Haematology: Is Ideal Body Weight the Preferred Metric?

Miss Lee Yi Jing

Nursing Challenges in Chemotherapy Administration for Haematology Patients

Puan Azizan binti Mohd Isa

Symptom Control and Goal-Concordant Care for Critically Ill Patients with Relapsed or Refractory Haematologic Malignancies

Dr Look Mei Ling

Panel Discussion

12.45 - 1.45 pm

Lunch Symposium 1 (Exclusive to Platinum Sponsors)

1.45 - 2.30 pm

Friday Prayers

EDUCATION SESSION 3

Plasma Cell Disorders

Myeloma: Is a Cure on the Horizon?

Moderator: Prof Dr Bee Ping Chong

Oral Presentations

Chairperson: Dr Wee Shiang Yui

When Genetic Disorders Collide: 

Understanding
Co-Inheritance and Its Impact

Moderator: Dr Nani Shahida

Nursing and Pharmacy
Education Session 3

Moderator: SN Selvemalini Muruvin

2.30 - 2.55 pm

2.55 - 3.20 pm

3.20 - 3.30 pm

Triplets, Quadruplets, and Beyond: Optimizing Frontline Myeloma Therapy

Dr Jay Suriar

Toward Functional Cure: Emerging Therapies in Relapsed and Refractory Myeloma

Prof Dr Chng Wee Joo

Panel Discussion

Laboratory Oral Presentations

When Genes Collide: Co‑Inheritance of SAO and Thalassemia—Does It Really Matter?

Dr Hafizah Hashim

Co-inheritance of Alpha and Beta Thalassemia

Dr Hafizah Hashim

Panel Discussion

Optimising Patient Readiness for Haematopoietic Stem Cell Transplantation:
A Nursing Perspective

KJ Norhafiza Razali

Comprehensive Nursing Care Following Haematopoietic Stem Cell Transplantation

Miss Jedidah Lieow Leng Meng

Panel Discussion

3.30 - 3.45 pm

Industry Showcase / Poster Walk

3.45 - 4.30 pm

Tea Break Symposium 1 (Exclusive to Gold Sponsors)

Tea Break Symposium 2 (Exclusive to Gold Sponsors)

4.30 - 5.30 pm

Advancing Clinical Haematology in Malaysia: Best Practices and Innovations

How Do Adjunctive Investigations Implicate Clinical Decisions?

Dr Boo Yang Liang, Hospital Sultanah Aminah

Allogenic Stem Cell Transplant in East Malaysia: Nuances and Challenges

Dr Khaiteri Raghunathan, Hospital Queen Elizabeth

Expanding Molecular Haematology Services: Balancing Equitable and CostEffective Precision Care

Dr Veena Selvaratnam, Hospital Ampang

Best Poster Presentation

6.30 - 9.30 pm

Faculty Dinner (By Invitation Only)

2.00pm - 2.30pm

CLINICAL

EARLY CAREER DEVELOPMENT

LABORATORY

NURSING AND PHARMACY

7.30 - 8.30 am

Registration

Expert Roundtable (By Invitation Only)

EDUCATION SESSION 4

Acute Lymphoblastic Leukaemia

How to treat AYA ALL?

Moderator: Dr Toh See Guan

Comprehensive Haemato-Oncology Care

Navigating Complications Across the Chemo–Transplant Continuum

Moderator: Dr Lily Wong

Advances in Molecular Testing

Diagnostics and Monitoring of Myeloid Disorders

Moderator: Dr Siti Fatimah binti Mohamed Kamaruzzaman

Nursing and Pharmacy
Education Session 4

Moderator: Ms Nor Shaheera Izaze

8.30 - 8.55 am

AYA Acute Lymphoblastic Leukemia:
Bridging Pediatric and Adult Protocols

Prof Dr Allen Yeoh

How I Manage Post-Transplant
Patients: Monitoring, Complications,
and Long-Term Care

Dr Sharifah Shahnaz

Pathology in Malaysia: Current Challenges, Future Directions, and Strategic Development

Dr Raudhawati Osman

Best Nursing Practices in CLABSI Prevention in Haematology Units

Matron Khairun Nisak binti Sairan

8.55 - 9.20 am

AYA ALL: Is Transplant Still the Gold Standard?

Prof Dr S Fadilah

How I Support Patients After Chemotherapy Toxicity Management, Monitoring, and Survivorship Care

Dr Tan Sui Keat

BCR::ABL1 Monitoring in Chronic Myeloid Leukaemia – Navigating the 2025 – 2026 Guidelines

Dr Siti Shahrum Muhamed Said

The First Hour Matters: Nursing Response to Suspected Neutropenic Sepsis

Dr Chang Chee Yik

9.20 - 09.45 am

High-Risk AYA ALL: Contemporary Challenges and Evolving Solutions

Dr Ng Chin Hin

How I Treat Infections in Haematology Patients: Practical Strategies for Clinicians

Dr Khaiteri Raghunathan

NGS in Myeloid Disorders

Dr Yuslina Matt Yusoff

Beyond Clinical Care: Counselling Essentials for Haemato-Oncology Nurses

Matron Chui Siew Queen

9.45 - 10.00 am

Panel Discussion

Panel Discussion

Panel Discussion

Panel Discussion

10.00 - 10.45 am

Tea Break Symposium 3 (Exclusive to Gold Sponsors)

Tea Break Symposium 4 (Exclusive to Gold Sponsors)

EDUCATION SESSION 5

Indolent Lymphoma

Current Practice and Future Directions

Moderator: A/P Dr Azlan bin Husin

Oral Presentations

Chairperson: Dr Boo Yang Liang

The Difficult Lymphomas

Practical Strategies in Trephine Biopsy Diagnosis

Moderator: Dr Syirah Nazirah

Lines that Save Lives:

Mastering Central Line Care in Haematology

10.45 - 11.10 am

11.10 - 11.35 am

11.35 - 12.00 pm

12.00 - 12.15 pm

Marginal Zone Lymphoma: Understanding the Biology of MZL – From Splenic to Extranodal Subtypes

Dr Leong Tze Shin

Advancements in Treatment of R/R Follicular Lymphoma

Dr Jerome Tan

Frontline Waldenstrom’s Macroglobulinemia in 2026: Chemoimmunotherapy or BTK inhibitors?

Prof Dr Ja Min Byun

Panel Discussion

Clinical Oral Presentations

T-Cell Lymphoma and Mimickers in Trephine Biopsy

Prof Dr Tan Soo Yong

Diagnostic Challenges of B-Cell and Hodgkin Lymphoma in Trephine Biopsy

Prof Dr Tan Soo Yong

Panel Discussion

Central Venous Access Device (CVAD) Care: PICC Lines and Chemoports

Practical Skills Masterclass:
Station 1: PICC line care
Station 2: Chemoport care

Panel Discussion

12.15 - 1.00 pm

John Bosco Lecture

1.00 - 2.00 pm

Lunch Symposium 2 (Exclusive to Platinum Sponsors)

EDUCATION SESSION 6

Marrow Failure Syndromes
From Diagnosis to Personalised Therapeutic

Moderator: Dato’ Dr Vijaya Shankar

Anaemia
Practical Management of Anaemia in Adults

Moderator: Dato’ Dr Goh Ai Sim

Transfusion Medicine
Precision Approaches to Alloimmunised Patients

Moderator: Dr Noraini Binti Amir

Nursing and Pharmacy
Education Session 5

Moderator: Mr Md Syamil Bin Ab Jalil

2.00 - 2.25 pm

Acquired Aplastic Anemia Frontline Treatment Optimization: IST + Eltrombopag and Beyond

Dr Chew Lee Ping

How I Treat Haemolytic Anaemia: A Practical, Case-Based Approach

Dr Yong Kar Ying

Red Cell Alloantibodies in Pregnancy: Clinical Challenges and Management

Dr Mohd Redzuan bin Abdullah

Unmet Needs in Malaysian Haemophilia Care: Transition from Paediatric to Adult Services

Puan Wan Alia Amalina Binti Adenan

2.25 - 2.50 pm

Advances in Haploidentical HSCT for Aplastic Anaemia

A/Prof Dr Linn Yeh Ching

How I Treat Iron Deficiency Anaemia: To Transfuse or Not Transfuse?

Dr Ahlam Naila Kori

Management of the Multiply Alloimmunised Patient: From Transfusion Strategy to Clinical Intervention

Dr Afif Bin Alam Faizli

Nursing Coordination in Multidisciplinary
Thalassaemia Care

Matron Chui Siew Queen

2.50 - 3.15 pm

Unmasking Hidden Hereditary Marrow Failure: Clinical Clues Across the Age Spectrum

Prof Dr Hany Ariffin

How I Manage Thalassemia: Comprehensive Management and Future Directions

Dr Liew Hong Keng

Rethinking Blood Use: The Way Forward in Patient Blood Management

Dr Jameela Sathar

Safe Blood Transfusion: The Nurse’s Role
from Bank to Bedside

Dr Nuraini Binti Sham

3.15 - 3.30 pm

Panel Discussion

Panel Discussion

Panel Discussion

Panel Discussion

3.30 - 3.45 pm

Industry Showcase / Poster Walk

3.45 - 4.30 pm

Tea Break Symposium 5 (Exclusive to Gold Sponsors)

Tea Break Symposium 6 (Exclusive to Gold Sponsors)

4.30 - 5.00 pm

Prize Giving and Closing Ceremony

Dr Haris Fadzillah
Johor State Domicilliary Palliative Clinical Advisor

Targeting the Genome: Precision Medicine Approaches in Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is entering a new era, driven by rapid advances in genomic understanding and the emergence of targeted therapeutic strategies. Once defined largely by morphology, AML is now recognised as a biologically heterogeneous and dynamically evolving disease, where genomic context increasingly determines clinical behaviour and treatment response.

This lecture will examine how genomic profiling has transformed contemporary AML practice, informing updated WHO, ICC, and ELN classifications and enabling more precise risk stratification at diagnosis. Moving beyond traditional paradigms, the session will highlight how insights into disease biology are now directly shaping therapeutic approaches.

Key clinical trials—including RATIFY, ADMIRAL, VIALE-A, and AGILE—will be discussed to illustrate how targeting oncogenic drivers, cellular dependencies, and metabolic pathways has led to meaningful improvements in survival across diverse patient populations. These advances underscore a paradigm shift from intensification of chemotherapy towards rational, biology-driven treatment strategies.

The growing role of measurable residual disease (MRD) as a sensitive and dynamic biomarker will also be explored. MRD assessment is increasingly central to modern AML management, refining prognostication, guiding transplant decisions, and redefining treatment endpoints beyond conventional remission criteria.

Finally, emerging therapies targeting transcriptional and epigenetic programmes, including menin inhibitors, will be presented as part of the next wave of precision medicine in AML.

This session aims to provide a clinically relevant and forward-looking overview of how genomics is reshaping AML care—moving the field towards more personalised, adaptive, and effective treatment strategies

Dr Tan Jin Hui
Johor State Domicilliary Palliative Clinical Advisor

Preventing Deconditioning and Promoting Functional Recovery in Haematology Patients: Practical Strategies for Nurses

Patients with haematological disorders, particularly those undergoing intensive chemotherapy, prolonged hospitalization, or stem cell transplantation, are highly vulnerable to rapid deconditioning due to fatigue, inactivity, muscle loss, anemia, , infection risk, neuropathy and treatment-related complications. Functional decline can develop early and may affect mobility, independence in activities of daily living, discharge readiness, and overall quality of life.

The aim of this session is to equip nurses and allied healthcare staff with strategies to reduce functional decline and help patients maintain mobility and independence throughout treatment. By including movement into routine care, nurses play an important role in preserving function and improving patient outcomes.

Dr Tan Sen Mui

Dr Tan Sen Mui obtained her basic medical degree locally and MRCP in UK. Started haematology training in the MOH in 2001 and subsequently further has her training in stem cell transplantation followed by research in cancer immunotherapy in University Wuerzburg, Germany.

She has special interest in cancer immunotherapy and actively participated in clinical trials. She joins private in SJMC following her retirement after serving more than 3 decades of government service, mainly in Hospital Ampang.

She is also the past secretary of Malaysian Society of Haematology (MSH) and member of the European Society for Blood and Marrow Transplantation (EBMT).

Dr Andy Tang
Consultant Haematologist
and Transplant physician from Sunway Medical Centre

Clinical management of venous thromboembolism (VTE) in 2026 centers on personalized, risk-adapted strategies, moving away from “one-size-fits-all” approaches toward shared decision-making, with a focus on maximizing safety and reducing long-term complications. The key nuances in the clinical management of VTE will be discussed, including anticoagulation nuances – choice and duration, and with a particular focus on  VTE in special populations/ unusual site venous thromboembolism. 

Dr Nur Aini Syakirah
Clinical Hematologist and Internal Medicine Physician

Dr. Nur Aini Syakirah Ahmad Shuyuti is a Clinical Hematologist and Internal Medicine Physician based in Kota Bharu, currently practicing at Hospital Raja Perempuan Zainab II, where she also leads clinical hematology services in the state. She holds a Fellowship in Clinical Haematology from the Malaysian Society of Hematology and a Master of Medicine (Internal Medicine) from Universiti Sains Malaysia, with a career spanning role from house officer to consultant specialist. In addition to heading the Hematology Unit and Medical Daycare services, she is actively involved in postgraduate medical training and serves as an honorary lecturer at multiple Malaysian universities. Her professional contributions extend to memberships in key national and international medical organizations, while her research portfolio includes extensive involvement in multicentre clinical trials as a principal investigator, co-investigator, and sub-investigator, focusing on hematologic malignancies, genetic studies, and novel therapeutic approaches.

Dr Amitav Mohanty

Current Practice of BCP-ALL MRD in Flow Cytometry and Next Generation Flow

Measurable residual disease (MRD) assessment has become an integral component of risk stratification and treatment response monitoring in B‑cell precursor acute lymphoblastic leukemia (BCP‑ALL). Over the past decade, flow cytometry based MRD has evolved significantly,driven by methodological standardization, advances in multicolor instrumentation, optimized antibody panels, and sophisticated data analysis platforms.

This session will review the current clinical practice of BCP‑ALL MRD by flow cytometry, with emphasis on the implementation of standardized EuroFlow based workflows that enable reproducible and harmonized MRD assessment across laboratories. The importanceof end‑to‑end standardization from sample preparation, antibody panel design, data acquisition, to reporting will be discussed, highlighting how such approaches reduce interlaboratory variability and support consistent clinical decision making. Advancementsin modern flow cytometers and analytical software have further strengthened assay robustness, allowing high‑event acquisition and objective, database‑guided analysis. These technologies facilitate improved sensitivity, accuracy, and reproducibility focusingon next‑generation, high‑sensitivity BCP-ALL MRD assays using Next‑Generation Flow principles, which push detection limits to below 10⁻⁵.

Finally, selected cases will be analyzed to demonstrate common diagnostic challenges, interpretative pitfalls. Together, these examples will illustrate how current and next‑generation MRD strategies can be effectively integrated into routine workflows to deliverclinically meaningful insights in BCP‑ALL management.

Ms Lee Yi Jing
Pharmacist, Hospital Ampang

Lee Yi Jing is a hospital pharmacist with extensive hands-on experience in cytotoxic drug reconstitution and oncology pharmacy.

With a proven track record at Hospital Ampang, she has led cytotoxic drug reconstitution in cleanroom environments, managed inventories and budgets, and implemented SOPs to enhance safety, quality, and regulatory compliance. Her roles have spanned clinical trial coordination under Good Clinical Practice, haematology medication management, chemotherapy counseling, and biannual health checks for CDR personnel. She also served in leadership as Hospital Ampang representative for the Oncology Pharmacy Working Committee at both Selangor state level and national level.

Dr Look Mei Ling
Johor State Domicilliary Palliative Clinical Advisor

The management of critically ill patients with relapsed or refractory haematologic malignancies presents a unique clinical challenge. Unlike many solid tumors, the trajectory of haematologic cancers is often characterized by high symptom burden and rapid clinical shifts. Every member of the interdisciplinary team play a pivotal role in ensuring effective symptom control while supporting care that remains aligned with patients’ goals and values.

This session aims to highlight common and distressing symptoms in this population—including pain, dyspnoea, delirium, nausea and vomiting—and discuss practical, evidence-based strategies for their management. Emphasis will be placed on safe and effective medication use, non-pharmacological interventions, deprescribing where appropriate, and navigating challenges such as limited oral routes.

Participants will also gain insight into approaches to elicit patients’ values and preferences when faced with a serious life-limiting illness. This is essential to ensure delivery of compassionate, patient-centred care that honours both symptom relief and what matters most to patients and their families.

Dr Hafizah Hashim
Consultant Haematologist
and Transplant physician from Sunway Medical Centre

Co‑inheritance of Alpha and Beta Thalassemia: Diagnostic and Clinical Implications

Co‑inheritance of alpha and beta thalassemia represents an important yet often
under‑recognized contributor to diagnostic complexity in populations with high thalassemia carrier rates. The interaction between reduced α‑globin and β‑globin synthesis can significantly modify hematological indices, leading to phenotypes that deviate from classical patterns expected for isolated alpha or beta thalassemia traits. Individuals with combined defects may present with milder microcytosis, borderline or atypical HbA₂ levels, or discordant red cell parameters that challenge routine screening algorithms and risk misclassification. These atypical findings underscore the limitations of relying solely on hematology and electrophoresis profiles. In certain instances, severe clinical phenotypes can arise, such as those caused by the co-inheritance of alpha-globin gene triplication/quadriplication .

Molecular testing remains essential for accurate genotype definition, particularly when α‑gene deletions ameliorate the severity of β‑thalassemia mutations or when β‑variants unmask underlying α‑thalassemia. Understanding these genotype–phenotype interactions is crucial for refining reflex testing strategies, improving laboratory interpretation, and ensuring precise carrier counselling. This presentation will highlight local case examples, discuss diagnostic pitfalls, and emphasize the importance of integrated hematological and molecular approaches. Strengthening awareness of co‑inheritance patterns supports more accurate risk assessment and enhances the effectiveness of national thalassemia prevention programs.

When Genes Collide: Co-inheritance of SAO and Thalassemia – Does It
Really Matter?

Southeast Asian Ovalocytosis (SAO) and thalassemia are two of the most common inherited red cell disorders in Malaysia, frequently encountered in both routine screening and targeted diagnostic workflows. While each condition independently produces characteristic haematological and morphological features, their co‑inheritance presents a unique interpretive challenge for laboratories and clinicians. As national programmes expand reflex
testing, antenatal screening, and molecular confirmation, understanding how these two conditions interact has become increasingly important.

This presentation will share cases of co-inheritance of SAO and thalassemia, specifically addressing the question of whether its presence genuinely affects diagnostic accuracy, phenotypic expression, or genetic counselling outcomes, or if it is clinically insignificant. We explore how SAO’s rigid erythrocyte membrane and distinctive ovalocytic morphology may mask, mimic, or modify the classical features of α‑ or β‑thalassemia carriers. Particular emphasis is placed on atypical red cell indices, misleading MCV/MCH patterns, and the potential for discordance between smear findings, Hb analysis, and molecular results. Beyond laboratory interpretation, the talk highlights implications for genetic counselling, especially in antenatal settings where accurate carrier identification is critical. Although most individuals with SAO–thalassemia co‑inheritance remain clinically well, the interaction between these genes can influence reporting clarity, partner testing decisions, and communication with families.

Ultimately, recognising when “genes collide” allows laboratories to refine reflex algorithms, avoid over‑diagnosis, and strengthen the reliability of national thalassemia screening. This session provides practical guidance for pathologists, scientists, and clinicians navigating this under‑appreciated but increasingly relevant diagnostic scenario.

KJ Norhafiza Razali
Department of haematology, Hospital Ampang

Optimising Patient Readiness for Haematopoietic Stem Cell Transplantation:
A Nursing Perspective

Haematopoietic Stem Cell Transplantation (HSCT) is a complex and high-risk treatment that requires careful patient preparation to ensure optimal outcomes. Nursing plays a key role in improving patient readiness before transplantation by providing education, psychological support, symptom management, and physical assessment. The lecture explores how nursing interventions can enhance patient understanding of the procedure, improve adherence to pre transplant requirements, and reduce anxiety. Effective communication, early identification of potential complications, and individualized care planning are essential components of nursing practice in HSCT preparation. By optimizing patient readiness, nurses contribute to improved transplant success rates, reduced complications, and better overall patient experiences.